Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
31. |
ECCT/24/02/09 | pionERA This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy. |
Principal Investigator(s) 1. Dr Sitna Ali Site(s) in Kenya University of Nairobi -Institute of Tropical and Infectious Diseases |
View |
32. |
ECCT/23/12/02 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL) |
Principal Investigator(s) 1. Dr. Maricianah Onono Site(s) in Kenya 1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 2. Walter Reed Army Institute of Research -Kericho Site (Kericho county) 3. KEMRI CCR – Butere Clinical Research Centre (Kakamega county) 4. Siaya County Referral Hospital (SCRH) (Siaya county) 5. Kenya Medical Research Institute Center for Microbiology Research (CMR) (Kisumu county) 6. KAVI - Institute of Clinical Research (KAVI - ICR) (Nairobi City county) 7. Kombewa Clinical Research Center, KEMRI, (Kisumu county) |
View |
33. |
ECCT/24/03/05 | 221163 PALISADE Long-Term Follow-Up of CAB LA for Participants in HPTN 083 and HPTN 084 CAB PrEP Studies at Risk of HIV Acquisition |
Principal Investigator(s) 1. Grace Mboya Site(s) in Kenya KEMRI Kisumu Clinical Research Site |
View |
34. |
ECCT/23/12/01 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL) |
Principal Investigator(s) 1. Prof Walter Jaoko 2. Dr. Lucas Thina Otieno 3. Prof. Kariuki Simon 4. Dr. Janet Nyawira Oyieko 5. Walter Otieno 6. Onono Dr. Marcianah 7. Dr. Lucas Thina Otieno 8. Prof. Kariuki Simon 9. Dr. Janet Nyawira Oyieko 10. Walter Otieno 11. Onono Dr. Marcianah Site(s) in Kenya 1. KAVI-Institute of Clinical Research, University of Nairobi (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 3. Walter Reed Army Institute of Research -Kericho Site (Kericho county) 4. KEMRI CCR – Butere Clinical Research Centre (Kakamega county) 5. Siaya County Referral Hospital (SCRH (Siaya county) 6. Kenya Medical Research Institute Center for Microbiology Research (CMR (Kisumu county) 7. Kombewa Clinical Research Center, KEMRI, (Kisumu county) |
View |
35. |
ECCT/23/12/04 | GBT021601 OLE An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants with Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial |
Principal Investigator(s) 1. Jessie Nyokabi Githanga 2. Videlis Nduba 3. Bernhards Ragama Ogutu Site(s) in Kenya 1. Gertude\'s Children\'s Hospital (Nairobi City county) 2. CENTER FOR RESEARCH IN THERAPEUTIC SCIENCES-STRATHMORE UNIVERSITY MEDICAL CENTER (CREATES (Nairobi City county) 3. KENYA MEDICAL RESEARCH INSTITUTE- CENTER FOR RESPIRATORY DISEASE RESEARCH(CRDR) (Nairobi City county) 4. KEMRI CRDR SIAYA (Siaya county) |
View |